Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy

Recruiting

Phase 2

Phase 3

Dipraglurant with LevodopaDipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy

Sponsor:

Addex Pharma S.A.

Code:

NCT04857359

Conditions

Parkinson Disease

Dyskinesia, Drug-Induced

Dyskinesias

Eligibility Criteria

Sex: All

Age: 30 - 70+

Healthy Volunteers: Not accepted

Interventions

Dipraglurant

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-01. This information was provided to ClinicalTrials.gov by Addex Pharma S.A. on 2022-05-20.